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Abstract
Background: There is increased international focus on improving the rigour of clinical practice guideline (CPG)
development practices. However, few empirical studies on CPG development have been conducted in low- and
middle-income countries. This paper explores national stakeholders’ perceptions of processes informing CPG
development for primary healthcare in South Africa, focusing on both their aspirations and views of what is
actually occurring.
Methods: A qualitative study design was employed including individual interviews with 37 South African
primary care CPG development role-players. Participants represented various disciplines, sectors and provinces.
The data were analysed through thematic analysis and an interpretivist conceptual framework.
Results: Strongly reflecting current international standards, participants identified six ‘aspirational’ processes that they
thought should inform South African CPG development, as follows: (1) evidence; (2) stakeholder consultation; (3)
transparency; (4) management of interests; (5) communication/co-ordination between CPG development groups; and
(6) fit-for-context. While perceptions of a transition towards more robust processes was common, CPG development
was seen to face ongoing challenges with regards to all six aspirational processes. Many challenges were attributed
to inadequate financial and human resources, which were perceived to hinder capacity to undertake the necessary
methodological work, respond to stakeholders’ feedback, and document and share decision-making processes.
Challenges were also linked to a complex web of politics, power and interests. The CPG development arena was
described as saturated with personal and financial interests, groups competing for authority over specific territories
and unequal power dynamics which favour those with the time, resources and authority to make contributions. These
were all perceived to affect efforts for transparency, collaboration and inclusivity in CPG development.
Conclusion: While there is strong commitment amongst national stakeholders to advance CPG development processes,
a mix of values, politics, power and capacity constraints pose significant challenges. Contrasting perspectives regarding
managing interests and how best to adapt to within-country contexts requires further exploration. Dedicated resources
for CPG development, standardised systems for managing conflicting interests, and the development of a political
environment that fosters collaboration and more equitable inclusion within and between CPG development groups are
needed. These initiatives may enhance CPG quality and acceptability, with associated positive impact on patient care.
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Background
Clinical practice guidelines (CPGs) have become a famil-
iar tool in policy and clinical practice. CPGs have a
range of purposes, intended to improve the efficiency
and cost-effectiveness of health system utilisation and to
decrease preventable mistakes [1]. They generally in-
clude statements of expected practice, benchmarks
against which individuals may audit and potentially im-
prove their practices, and guidance regarding undertak-
ing given tasks [1]. CPGs were historically built mostly
on expert opinion, which included variable (and often
selective) reference to research evidence [2–4]. However,
over the last decade there has been increased focus on
improving the quality of CPGs and the methodological
rigour of their development [5]. Globally, health system
pressures are increasingly demanding that resources are
effectively allocated and based on research evidence of
‘what works’ [6]. Within this context, there is growing
recognition that high quality, evidence-informed CPGs
can serve as practical vehicles for meeting these de-
mands and reducing the gap between evidence, policy
and best practice [1, 7].
This maturing CPG development culture is evidenced
by the various recent attempts made by well-credentialed
international collaborations to standardise and improve
the credibility of CPG development practices [8]. Between
2011 and 2013, three sets of standards were independently
proposed to assist CPG developers in addressing key is-
sues of quality, as follows: the Institute of Medicine intro-
duced 8 standards for guideline development [9], the
Guidelines International Network produced 11 relatively
similar standards [10], and McMaster University compiled
a checklist of 18 topics and 146 items to guide devel-
opers [1]. Concurrently, two checklists (the AGREE II
instrument [11] and iCAHE guideline quality checklist
[12]) were developed, both providing tools to evaluate
the process of CPG development and the quality of
its reporting. While there are differences between
these standards, they are unified in advocating for
CPG development to be guided by transparently con-
structed and evidence-informed approaches that have
a clear and applicable scope and are integrated with
stakeholder consultation [8].
Despite a growing knowledge industry centred on
CPG development, little is currently known about this
topic in low-resource settings generally and in
sub-Saharan Africa (SSA) in particular [13–15]. While
numerous studies in high-income countries (HICs) have
investigated the quality of CPGs and their development
methodologies in a variety of settings [16], very few of
these studies have been conducted in SSA. For example,
a systematic review evaluating 42 guideline appraisal
studies, including 626 guidelines published between
1988 and 2007, found only 6 guidelines across the
studies were from Africa [17]. Nevertheless, the situation
is beginning to change, with the topic receiving more
empirical attention in SSA over the last 5 years. For ex-
ample, recent quantitative reviews have evaluated the
quality of CPGs for priority diseases in SSA generally
[13] and in South Africa specifically [18]. Similarly, cer-
tain qualitative studies have provided analyses of the de-
velopment processes of guidelines for eclampsia
treatment and malaria control in 3 SSA countries [19,
20], as well as for maternal health [21], lay health
workers [22] and primary care [23] in South Africa.
This body of research in SSA has revealed many simi-
lar shortcomings in the quality of CPGs and their devel-
opment as those identified in studies in HICs, including
with regards to their methodological rigour, editorial in-
dependence and applicability to local practice [13, 18].
However, it has also shed light on certain unique,
context-specific challenges facing CPG development in
the region. For example, complex political environments
and interests, bureaucratic processes and budget strug-
gles, a lack of locally relevant evidence, and limited skills
have all been shown to hinder CPG development in SSA
[19–23]. Taken together, the findings from this small
body of research suggests that more knowledge is
needed on the specific circumstances, processes and pri-
orities underpinning CPG development in different SSA
settings, and the factors that could improve their con-
struction. This knowledge will help pave the way for bet-
ter focused, locally tailored and effective interventions to
improve CPG quality and development, and associated
positive impact on healthcare practices and outcomes in
the region.
Against this backdrop, the aim of the current study
was to explore national stakeholders’ perceptions of
current CPG development activity for primary health-
care (PHC) in South Africa. More specifically, it sought
to investigate their perceptions of the processes that
should inform national CPG development, and their
sense of what is actually occurring. This study is a
sub-study of a broader qualitative study that provided an
overview of the current landscape of PHC CPG activity
in the country [23]. This sub-study explores the issue of
CPG development in more depth, with a focus on the
perspectives of stakeholders operating at the national
level. Both the larger study and this sub-study form part
of the South African Guidelines Excellence (SAGE) pro-
ject, which aims to understand and improve the develop-
ment, adaptation, implementation and use of PHC CPGs
in South Africa [24].
Research context
CPGs have been part of South African clinical practice
for many decades. Formal national CPG processes were
put in place in the mid-90s in a bid to address historical
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inequity in health service delivery in the nine provinces.
South Africa’s National Department of Health (NDoH)
currently spearheads several primary care guideline pro-
grammes, including condition-specific guidelines (e.g.
malaria, HIV, tuberculosis) and the Essential Medicines
Programme, which develops comprehensive Standard
Treatment Guidelines for rational prescription at all
levels of care in an equitable, cost-effective manner.
Additionally, academic departments and professional so-
cieties develop CPGs, addressing gaps in what is avail-
able from NDoH.
Methods
This study adopted a qualitative approach to understand
the phenomena under investigation as experienced and
perceived by the actors involved. The methods have
been described in detail elsewhere [23], and thus a brief
summary is provided here, together with a more detailed
description of the analysis methods used in this paper.
Participants and data collection
The sample included 37 participants from a range of
disciplines, stakeholder groups and provinces in the
country (Table 1). Participants were approached in
their capacity as contributing to national South Afri-
can CPG development. Most were from academic
contexts and providing expert input to guideline
panels, many had been involved with this for more
than 15 years. Besides the government players, the
other participants usually held multiple roles, such
that, in addition to CPG development, some were re-
sponsible for research, clinical teaching and senior
management roles in academic or private sector con-
texts. Only one government member had a specific
role in CPG implementation. Data collection com-
prised in-depth individual interviews, conducted to-
gether by two interviewers per interview. The
interviews were based on a semi-structured interview
guide, including open-ended questions and tailoring
to the experiences of each specific interviewee. Key
themes explored included players involved in CPG ac-
tivity, CPG nomenclature and terminology, as well as
the processes, contexts and values underpinning CPG
development, adaption, contextualisation, implementa-
tion and use in South Africa.
Data analysis
The data for this paper were analysed through thematic
analysis [25] and the lens of an interpretivist conceptual
framework [26].
The larger SAGE project previously developed a list of
conceptual components (‘open coding’), guided by the re-
search objectives of the SAGE project. After immersion in
the transcripts, codes related to ‘CPG development’ within
the SAGE coding framework were used to code the tran-
scripts through multiple line-by-line readings and with the
aid of Nvivo10, a software programme that aids in the
management of qualitative data. Additional or revised
codes were developed iteratively as determined by the data
and added to the coding framework. Initial and revised
codes were then collated into potential themes and pro-
duced into an overall ‘thematic map’ to guide further ana-
lyses. Using the thematic map, the themes related to the
processes of developing CPGs were identified, named and
extracted. For each theme, the focus was on capturing
how the participants were making sense of CPG develop-
ment, and the values and concerns they attached to this
issue. While we focused on identifying common themes,
we also paid attention to the presence of potential diver-
sities in participants’ perspectives. Further analyses were
then undertaken to check if these ‘fitted’ in relation to the
coded extracts, to refine the specifics of each theme and
their relationships with each other, and to contextualise
these themes within the other emerging topics in the
dataset.
Throughout the analysis process, we attempted to ad-
here to the methodological principle of reflexivity [27].
At regular intervals SC, TK and KD jointly discussed
and further unpacked the emergent themes. Along with
facilitating verification, validation and refinement of
ideas, these discussions also provided opportunities for
the researchers’ interests and taken-for-granted assump-
tions to surface and subsequently be examined. Such re-
flexivity was facilitated further by the different roles the
researchers occupied in relation to the research, an
awareness of which provided for an illuminating inter-
play of emic–etic viewpoints. TK, KD and AA had
jointly conducted most interviews, both had prior know-
ledge of many participants and TK is involved with CPG
activities within academic and government settings. KD
and AA are social scientists, and had been involved from
project inception with planning, interviews and initial
analysis. KD has been involved with health policy
Table 1 Description of stakeholders sampled (n = 37) [23]
Background discipline Medicine (n = 19), pharmacy (n = 5), nursing (n = 4), allied health (n = 3), dentistry (n = 1), nutrition (n = 2), non-
clinical managers (n = 3)
Sectors and stakeholder groups National (n = 10) and Provincial Department of Health (n = 2), Professional Societies (n = 6), Private sector
(pharmaceutical n = 1 and medical schemes n = 2), academia (n = 14), non-governmental organisations (n = 2)
Provinces represented Eastern Cape (n = 1), Gauteng (n = 16), Kwazulu-Natal (n = 3), Western Cape (n = 17)
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analysis in another project. AA straddles social science
and quantitative research in her role at the Cochrane
Centre. SC became involved in the research only at the
analysis stage and had little prior knowledge of the local
CPG landscape. SC’s a priori unfamiliarity with the inter-
view content enabled the data to be explored openly and
with a ‘fresh’ perspective. Moreover, the interaction be-
tween researchers with both ‘distance’ and ‘closeness’
allowed for previous understandings to be opened-up
and questioned, and for our own positioning and associ-
ated shaping of the research process and outcomes to be
critically reflected upon.
Results
The analysis revealed six ‘aspirational’ processes that
participants perceived to be most important when devel-
oping CPGs for PHC in South Africa, namely (1) evi-
dence, (2) stakeholder consultation, (3) transparency, (4)
management of interests, (5) communication/co-ordin-
ation between different CPG development groups, and
(6) fit-for-context. We describe each process separately,
unpacking both participants’ aspirations and their views
of the extent to which each process is, in reality, under-
pinning the development of CPGs. To preserve anonym-
ity, certain phrases have been removed from quotations
and replaced with alternative text in square brackets.
Evidence
The concept of an ‘evidence-based approach’ featured
prominently in participants’ narratives. An overwhelm-
ing majority of participants, across stakeholder groups,
strongly emphasised that CPGs should be driven by sci-
entific evidence on the effectiveness, safety and
cost-efficiency of a clinical process or treatment. The no-
tion that CPGs “should be evidence-informed” (INT33),
“scientifically rigorous” (INT14) and “guided by the
current evidence-base” (INT25) was widespread, or as
one government participant succinctly stated: “The de-
partment stand is that whatever policies or guidelines we
develop are evidence based” (INT22).
A common sentiment, particularly amongst academic
and government participants, was that the development
processes of many national CPGs have evolved over
time, increasingly being informed by a more robust
evidence-informed approach. Many CPGs were de-
scribed as “coming a long way” (INT06) or having “over
time, become more and more evidence based” (INT4).
Whilst perceptions of progress were common, the need
for further improvement was also communicated. More
specifically, many participants expressed reservations
about certain CPGs in the country, and the extent to
which they are being guided by an evidence-based
approach.
Various reasons were provided for the inadequacies
participants saw with regards to the certain CPGs’ use of
evidence. Here, a lack of dedicated time and funding, as
well a scarcity of skills for quality CPG development
emerged as overriding themes. The interviews were satu-
rated with accounts of how those involved with CPG de-
velopment are often doing it voluntarily and afterhours,
and there is thus limited capacity to undertake the ne-
cessary methodological work:
“People are stretched… we all have full time jobs and
we’re doing it, not for money, not for kudos… so you
can’t expect the kind of rigor that you’d like to see”
(INT04, Academic)
Along with limited time and funding, many partici-
pants also highlighted how there is a dearth of skills in
the country for synthesising and incorporating evidence
in CPGs. Many spoke about the “lack of competent
people who are able to do this kind of work at a national
level” (INT03) and that “the distribution of people with
skills in evidence-based medicine… is quite a problem in
the country” (INT15).
The shortages of skills in evidence-based medicine
within the NDoH, in particular, emerged as a key issue
amongst government participants. Many attributed this
deficiency to what they perceived as inadequate, or even
non-existent, in-house training. As one participant put it
succinctly:
“We have also not been trained on the processes that
need to be followed”
(INT37, NDoH)
Similarly, another government official replied, when
asked whether he received training in evidence-based
medicine:
“No training, no training! You learn on the job… when
you see courses being offered… in most cases it’s out
of your own pocket because it’s outside of the HR
development planning process”
(INT22, NDoH)
Stakeholder consultation
There was considerable agreement amongst participants
and across stakeholder groups that widespread stake-
holder consultation also needs to form an essential part
of CPG development. Many participants spoke at length
about why this is critical. Along with serving as an
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important peer-review mechanism, widespread consult-
ation was seen as essential for facilitating ‘buy-in’:
“I think a key for any guideline is inclusivity. Because
if you want people to embrace your guideline, it’s
much easier if they were part of it than if you just
thrust it upon them”
(IN19, Professional society member)
Several participants felt that it is particularly important
to include the end-users of CPGs in consultation pro-
cesses to ensure that guidelines are “practical… at imple-
mentation level” (IN32), are “acceptable to those
implementing them” (INT22) and “so nurses understand
what you want to say” (INT05).
Many participants spoke about their own CPG devel-
opment processes as involving stakeholder consultation,
one which they perceived to be fairly wide and extensive.
Participants spoke about “our strategy of wide consult-
ation” (IN22), that “we are fairly meticulous about circu-
lating our guidelines to all organisations concerned”
(INT17) and that, ultimately, “Anybody who is on the
ground, who feel they have something to contribute here,
they will” (INT16).
While there was a tendency amongst participants to
describe their own consultation processes in relatively
positive terms, a more complex picture of stakeholder
engagement in CPG development also surfaced. This
emerged most prominently when participants talked
about their experiences with the development processes
of other CPG development groups. This also materia-
lised in certain participants’ narratives of their own con-
sultation processes, where certain reservations were
revealed.
Many participants spoke about various other CPG de-
velopment groups as comprising “a very non-consultative
process” (INT18) or as being “an authoritative entity, who
never… considers clinicians’ input” (INT17). Others de-
scribed the inherent unresponsiveness of certain CPG
groups, and their inadequacies in responding to people’s
input. As one participant said:
“The sense that we’ve had with all the people we’ve
engaged with is that you will send a lot of feedback to
the [particular CPG development group] but you’ll get
no formal response to any of your feedback”
(INT03, Academic)
This failure to provide adequate feedback was recognised
by certain participants with regards to their own consult-
ation processes. Many explained how there actually is a
very rigorous process for considering and incorporating
stakeholder feedback, and yet due to capacity constraints,
they are limited in their ability to adequately respond. As
one participant indicated, acknowledging that this is a
problem:
“People will give a comment, but when the book is
published they see that their comment hasn’t been
incorporated… it’s not that the committee didn’t
consider the comment… but because of capacity
constraints, we can’t respond to each and every
comment… but we’ve got to ask ourselves: how do we
make it more publicly available that we have looked
at your comment… without responding to each and
every person on each and every point?”
(INT16, NDoH)
Certain participants conveyed other reservations with
regards to their own consultation processes. Some ques-
tioned the level of inclusivity of their engagement pro-
cesses, highlighting the problems they have engaging
with particular groups. For example, many professional
society participants alluded to the struggles they encoun-
ter consulting with government:
“I think the process should be more inclusive… that
is certainly the weakness of our current situation.
But engaging with government is an extremely
difficult process… there are very, serious barriers of
communication with government”
(INT18, Professional society member)
Many other professional society participants shared
this participant’s view, providing similar accounts of how
“communication with the DoH has been shocking”
(INT19), and how “there should be an easier way for us
to engage government” (INT14).
Certain government participants alluded to the dif-
ficulties they experience around engaging with vari-
ous groups. Some felt that particular provinces,
other than the Western Cape and Gauteng, are hard
to engage with and ultimately remain weak in their
participation:
“I think there are weaknesses within the consultations
at provincial level… in a province like Western Cape,
it is done widely, but in other provinces, not really that
much”
(INT22, NDoH)
Other government officials felt that the end-users of
CPGs are another specific group that they have found
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hard to reach and are unsatisfactorily consulted, as
reflected by this participant’s comment:
“I don’t think we have found a better… mechanism of
really engaging the people who are… at the frontline of
implementation… I think a lot of programmes struggle
with what will be the best way of engaging the end users”
(INT36, NDoH)
Those participants who expressed uncertainties about
their own stakeholder consultations suggested various
aspects of the engagement process that might limit its
inclusivity. For example, some indicated that the process
tends to favour those who have the capacity to provide
written feedback and the ability to use the internet, as
depicted in the following two statements:
“So [a particular CPG development group] have…
collated a whole lot of emails and they send it
out and also make it available on the website…
but it just depends sometimes though, like nurses
in rural areas do not have the capacity to connect
online”
(INT33, Academic)
“The same usual suspects will give their comments
because that’s their comfortable way of engaging… but
there are other people who engage differently… maybe
they don’t want to write something so they may need a
different strategy”
(INT16, NDoH)
Relatedly, other participants suggested that the time
given to stakeholders to provide feedback is insufficient,
and may be an additional barrier to more widespread
and inclusive consultation:
“The consultation process doesn’t always look valid
because there wasn’t given time to comment”
(INT14, Professional society member)
Transparency
It was widely suggested that CPG development also
needs to be guided by a clear, transparent process so
people can understand decision-making processes. Many
participants spoke about the fact that “people need to see
the validity of the process” (INT01) and that “fair trans-
parency is a critical component of guideline develop-
ment” (INT23), or as one participant stated:
“I think the most important thing is that… we have to
have a very transparent, clear process… a level of
transparency that… someone can understand why
decision were made”
(INT08, Professional society member)
The dominant view expressed by participants in all the
stakeholder groups was that CPG development in the
country tends to lack sufficient transparency. Descrip-
tions were commonplace about how CPG construction
processes are “very untransparent… completely opaque
to everybody” (INT14), “a complete mystery” (INT3), or
as described by one participant:
“I have issues with the [particular CPG development
group] not being transparent… what we need is to
make that process visible, because it’s actually, they
have terms of reference, they have criteria, they go
through a very evidence-based process”
(INT30, Academic)
Like this participant, many other participants conveyed
a sense of trust in the rigour of various CPG develop-
ment processes, and yet perceived there to be a signifi-
cant gap in the documentation and sharing of the logic
behind the decisions. Many suggested that there is a
need for greater communication about exactly how the
process unfolded, so that people can better appreciate
the credibility of CPGs:
“I think the communication… there’s a lot of
misconceptions… but just talking to people and telling
them, okay, this is how we do it, then they get the
insights… that there’s a rigorous process”
(INT16, NDoH)
Not many participants provided reasons for why the
process is not as transparent as it should be, despite
probing by interviewers. The few that did reflect on this
issue suggested, once again, that limited time and fund-
ing was the cause, with stakeholders lacking the capacity
to adequately record and elucidate decision-making
processes:
“So there is an awful lot of work going on… but not a
lot of capacity to engage in a very clearly documented
and open process… but we do need to consider what
the best means is of documenting evidence and then
sharing that evidence in order to get more buy-in”
(INT21, Academic)
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Given that few participants provided details on why
transparency is an issue, it is unclear whether this view
is shared by others.
Management of interests
A few participants stated explicitly that the declaration
and management of interests need to form a key aspect
of CPG development, so that decision-making processes
are not influenced by inappropriate forces:
“Your governance has to be clear… people have to
know… what interest they need to declare, what
information they need to keep confidential… and the
reason… is because we don’t want undue influence on
our decision-making processes”
(INT16, NDoH)
Although not overtly stated in most cases, many par-
ticipants clearly conveyed the view that vested interests
need to be considered and managed when producing
CPGs. The interviews were replete with descriptions of
people’s conflicts of interests and the role these are play-
ing in CPG development. Participants spoke about these
interests as being both personal/intellectual and finan-
cial. In terms of the former, many described in detail the
“personal agendas” (INT5), “little hobby horses” (INT6)
and “vested interests” (INT14) people involved with CPG
development across the board have:
“There’s a whole lot of politics… we have all these
competing interests… even us sitting at the university…
we have these different groups that have their own
agenda… to defend their turf”
(INT25, Academic)
More specifically, many participants described how in-
dividuals developing CPGs may be involved with specific
programmes or research projects, and often push for
guidelines to incorporate these. As articulated by this
participant:
“There’s a lot of individuals or research institutions
pushing their own agendas… like those on drug
development, clinical trials… the expectation is that
you would change your policy based on that… and it
creates problems for us in terms of determining what
should be in the guidelines… we’re put under pressure”
(INT22, NDoH)
Numerous participants provided analogous ac-
counts, similarly highlighting the problems they have
around managing personal interests. Certain partici-
pants also expressed uncertainty about how these
agendas can and should be managed, as communi-
cated by this participant:
“We talked about this… how we probably need to also
disclose grant conflicts of interest because if you’re
sitting on a study that is, you know, if you change [the
policy], your study is not going to continue, right?…
But, then everybody has some sort of bias, so I don’t
know what the ultimate answer is, like how do you
make this so completely transparent”
(INT08, Professional society member)
In addition to interests of a personal or intellectual na-
ture, many participants were also particularly concerned
about financial interests and the fact that a “massive
amount” of guidelines are “driven by industry” (INT20).
As aptly revealed by this remark:
“My colleagues… they don’t see the harm if industry
comes and does this. You know, it’s so insidious…
they’re doing subliminal advertising, and people don’t
get how that can influence how you make a decision”
(INT16, NDoH)
When talking about the pervasiveness of financial in-
terests, many participants were particularly worried
about professional society groups in this regard. Com-
ments about such groups having “lots of apparent influ-
ence of industry” (INT21) and “being influenced
tremendously by industry” (INT18) were ubiquitous,
along with descriptions of how professional society
CPGs are “essentially drug company driven” (INT19).
Many participants also questioned the sufficiency of the
extent to which the financial interests operating amongst
professional societies are being managed:
“In many instances, if not most instances, there is no
process to deal with potential conflicts of interest”
(INT15, NDoH)
Certain professional society participants themselves
expressed analogous concerns, with some conveying
similar apprehensions about the presence and inad-
equate management of financial interests within their
own societies. As one member acknowledged:
“It depends on the integrity of the individual… you
know, I think it’s very glib now, the declaration of
conflict of interest. It goes up in the first slide and you
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don’t even see it. Here’s my title and here’s my conflict
of interest. It’s very glib”
(INT18, Professional society member)
In a similar manner, when asked directly about his ex-
periences of conflict of interests within his own society,
another participant explained:
“I’m trying to remember… whether we actually had to
declare a conflict of interest. I don’t think we did”
(INT19, Professional society member)
This participant went on to articulate why conflicts
were not declared within his society, outlining some
of the difficulties in this regard. According to him, it
would be “too numerous” as “everyone is going to have
to have received funding from someone for something”.
He explained that “all those would all have to be de-
clared … which would take the first four pages of the
guideline”. He indicated further that “if you try and
put too many rules in place”, you will ultimately cre-
ate a hindrance to CPG development, or as he put it:
“It then trumps people’s desire to actually do the
guidelines”.
Thus, while most participants felt that management of
interests is a key activity for CPG development, certain
stakeholders had a different perspective. As with the par-
ticipant above, some questioned the value as well as the
practicality of declaring and managing conflicts of
interests.
Communication and co-ordination between CPG
development groups
Various participants stressed the importance of commu-
nication and co-ordination between different CPG devel-
opment groups, suggesting that “those writing guidelines
must speak to each other” (INT37) and that “there’s got
to be absolute linkage between programme guidelines”
(INT27). This was identified as essential for ensuring
“harmony between guidelines” (INT03) and that “we
don’t give confusing messages to practitioners” (INT15).
Many participants felt that it is particularly important
for CPG developers to communicate with the Essential
Drug List (EDL) committee, as exemplified by this
comment:
“If I was redesigning the system, I would have a…
process for guideline development that has a clearing
house effect that goes through the EDL, who then
issues it”
(INT14, Professional society member)
There was much consensus amongst the participants
that, in reality, communication and coordination be-
tween different CPG development groups is noticeably
absent. The general picture that emerged was one of
fragmentation, whereby a diverse range of groups are de-
veloping CPGs relatively independently of each other.
Many described this disconnect as occurring between
the private and public sectors:
“Private, they do their own thing, only… where they
don’t have a choice… or where they absolutely
don’t know, only then do they then refer to the other
guidelines”
(INT06, NDoH)
Other participants spoke about divisions within the
NDoH and the lack of communication across govern-
ment departments. CPG development processes within
the NDoH were referred to as “siloed in a way that
there’s not really good communication” (INT08), “dis-
jointed pockets of activities” (INT15), or as one partici-
pant proposed:
“There is a two-parallel process from the department
of health, and the one side is the formal process and
on the other side you’ve got stroke management,
malaria management, HIV management… so all are
little silos inside other silos”
(INT20, NDoH)
At the same time, many participants felt that some,
but not all, CPG development groups are communicat-
ing with the EDL, or as two participants put it “commu-
nication is stronger with some programmes than with
others” (INT37) and “often programmes haven’t checked
the EDL” (INT20). This view was shared by a member of
the EDL committee who, when asked whether CPGs are
being circulated through the EDL, responded:
“It doesn’t happen with all national departments. So
[particular government department], yes, but I’m still
struggling to get [particular government department]
to send their guidelines to us for peer review”
(INT17, Academic)
This lack of communication between CPG developers
was perceived to result in the replication of guidelines
and a duplication of work, or in the words of one par-
ticipant: “discrete pockets of people reviewing the same
data” (INT11). It was thought to also give rise to contra-
dictions between CPGs, with “a whole host of conflicting
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recommendations across the different guidelines”
(INT03) and guidelines that “don’t fit together… to make
a coherent whole” (INT02).
Some participants attributed this situation to a matter
of timing, suggesting that CPG inconsistencies are re-
lated to the fact that different CPGs are developed and
updated “according to different schedules” (INT37) that
are “not always in sync” (INT15). However, other partici-
pants conceived the problem to be of a more political
nature. That is, it was suggested that the difficulties stem
from the complex relations of power and control that
exist within the CPG development arena in the country,
as one participant proposed:
“There are lots of interest groups competing for control
of this, and that’s why partly it hasn’t been cohesive…
The department of health, because they are in the HIV
field, I think wants to keep some of that to themselves.
The TB people wanted the TB to themselves… there’s
just lots of competing interests around these things.”
(INT14, Professional society member)
Fit-for-context
A final issue that featured prominently in the interviews
was the need for CPGs to be contextually relevant, and
thus the necessity that CPG developers think about
“what is suitable for our context” (INT01) and “is this
relevant to our situation” (INT37), or as specifically
stated:
“We feel guidelines need to be relevant to South Africa,
I mean, our situations are different and our cost
constraints are different, and it has to be relevant”
(INT18, Professional society member)
When describing CPG development processes, there
was considerable agreement amongst participant groups
that most CPGs in the country draw heavily on inter-
national guidelines and what is being recommended glo-
bally, particularly by WHO:
“In most cases guidelines are guided by the WHO
recommendations”
(INT22, NDoH)
Although there was widespread consensus that CPGs
in South Africa are usually based on what is being done
and advocated for internationally, there were divergent
views amongst the participants about the use of this ap-
proach. Some were critical of this tendency, suggesting
that we should not be relying on other sources to do the
methodological work of CPG development:
“I would say there’s an over reliance on other
guidelines without looking at the primary evidence”
(INT37, NDoH)
Other participants expressed frustration with the dom-
inance of global discourse, and the pressures they feel to
conform to these. This was aptly conveyed by one par-
ticipant who lamented:
“WHO is a really sore point with a lot of our experts
because they’re writing policy for Africa… I mean we
do not lack technical expertise… and we have the
evidence… I think our experts should be the ones
driving the decisions”
(INT14, Professional society member)
In contrast to these perspectives, other participants
supported the widespread use of international guidelines
when developing local CPGs. Here, the common view
was that it is unwarranted to repeat the work already
done by other, well-respected organisations:
“It’s not necessarily developing all the guidelines from
scratch… because if it’s there, why reinvent the wheel”
(INT25, Academic)
Many participants shared this view, yet suggested fur-
ther that international CPGs should be used but a process
of contextualisation should ensure the “critical appraisal
of international guideline” and “local adaptation” of these
so they suit out local circumstances (INT37). As two pro-
fessional society participants explained:
“What I have been pushing for a lot is to say, take
the WHO guidelines… and then adapt them to South
Africa”
(INT14, Professional society member)
“What we want to do, [which] we haven’t always
historically done… is we need to take WHO as the
starting point, the baseline and then adapt from there”
(INT08, Professional society member)
As suggested by these two participants, and sharing
the views of other participants, the process of adapting
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international CPGs is currently limited, something which
was perceived to be a key area for improvement. How-
ever, there were some participants who indicated that
they do undertake such a process, stating, for example,
that “we use international ones and then adapt for this
context” (INT25) or that “a lot of it is based on WHO
recommendations and then we decide whether it is suit-
able for our context” (INT30). Despite considerable
probing, details of exactly how this process of appraisal
and adaptation is undertaken was difficult to gage, with
participants providing little information in this regard.
While the importance of local relevance was widely
emphasised, the majority of participants indicated, sim-
ultaneously, that CPGs should not be adapted for con-
textual difference within South Africa. With one
exception, all participants emphasised strongly that “we
don’t want disparity between provinces” (NT16) and that
“you can’t have a different standard for Limpopo [poorly
resourced province] and for the Western Cape [well-re-
sourced province]” (INT04). In justifying this view, many
participants explained how the overriding objective of
post-1994 CPGs is to promote justice and ensure every-
one has access to the same standard of care, so as to re-
dress the historical inequities instigated by the apartheid
regime. Thus, according to them, adapting CPGs for
inter-provincial contextual differences would be going
against the very socio-political role CPGs are meant to
play in the country. However, one participant, a govern-
ment official from Kwa-Zulu Natal, had a contrasting
perspective, explaining how South African provinces
have vastly different resources, cultures and infrastruc-
ture, and that a failure to accommodate these diversities
could have dire consequences:
“Our needs might not necessarily be the exact same
as other provinces… and sometimes you find that a
national guideline is… not tailored for the province…
and the moment you say you must without considering
the situation in the province it will make a situation
worse, it won’t help us”
(INT32, NDoH)
Discussion
This paper explored national stakeholder participants’
perceptions of the processes informing CPG develop-
ment for PHC in South Africa, focusing on both their
aspirations and sense of what is occurring ‘in reality’.
While the analysis sought to identify common themes, it
also paid careful attention to potential divergences in
perspective.
The findings revealed considerable agreement amongst
participants about the processes that should inform CPG
development in the country. While there were differences
in the relative importance given to each of the six aspir-
ational processes identified, all were highlighted as import-
ant by the 37 participants. These processes strongly reflect
current global standards regarding guideline development,
and their emphasis on inter alia use of evidence, stake-
holder involvement, transparency, applicability and editor-
ial independence/managing conflict of interest [1, 9, 10].
The importance of ‘evidence’ was a particularly prominent
theme. This widespread culture of evidence-based medi-
cine amongst our respondents, and similarly revealed in
other policy development studies in South Africa [21, 28],
stands in sharp contrast to the literature describing a lack
of access to and awareness of evidence in many low- and
middle-income countries [29, 30].
Another theme that featured strongly in the partici-
pants’ narratives was the importance of CPGs to be ‘fit
for context’. While there were divergent views about the
pervasive use of international guidelines, and evident
tensions around whether CPGs should accommodate
provincial differences, the imperative to consider ‘con-
text’ when developing CPGs was a common viewpoint.
There is growing interest within the international CPG
methodology literature in ‘contextualisation’, with various
frameworks recently developed to guide the adaption of
CPGs developed in one country to other settings [31,
32]. However, these approaches tend to be designed for
the reconfiguration of CPGs to new, but contextually
similar, settings [5, 33]. They thus provide little guidance
on how CPGs might be transferred across settings with
different healthcare policies and contexts. The Filipino
CPG implementation project [33] and Practical Ap-
proach to Lung Health in South Africa initiative [34] are
examples of the few attempts that have been made to
develop practical approaches for contextualising CPGs
developed in HICs to low- and middle-income countries.
More of these kinds of initiatives are clearly needed, as
evidenced by participants’ uncertainty in this present
study around how to adapt CPGs developed in HICs for
effective use in South Africa.
A particularly noteworthy finding from this study was
the chasm between participants’ aspirations of how
things ‘should be’ and their views of how things are ‘in
reality’. While many spoke about a transition towards
more robust processes, the general view was that CPG
development still faces significant challenges with
regards to all six aspirational processes highlighted.
Across all six thematic areas, there were suggestions for
how best to bridge the gap between what is, and what
should be happening, in CPG development processes;
we explore these suggestions in another paper [23]. Con-
curring with other guideline development research in in
SSA [19–23], many of the problems identified were at-
tributed to a lack of financial and human capacity. More
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specifically, the paucity of dedicated time, funding and
skills for CPG development was perceived to hinder the
methodological work of synthesising evidence, effectively
responding to stakeholders’ feedback, and transparently
documenting and sharing decision-making processes. A
lack of resources is not a unique issue affecting CPG de-
velopment in South Africa. Despite the introduction of
key health policy reforms, human and financial resource
challenges continue to hamper progress in all areas of
healthcare delivery [35]. The findings in this paper sug-
gest that, like in other areas of healthcare, there is a
need for greater dedicated resources for CPG develop-
ment to build capacity and support for the delivery of
high quality CPGs in South Africa.
In addition to resource limitations, our findings sug-
gested that current challenges facing CPG development
are also intimately linked with the complex web of polit-
ics and power operating within the CPG arena in the
country. For example, the fragmentation within govern-
ment programmes and between public and private sec-
tors was attributed, in part, to issues of control and
ownership. Different groups were described as interested
in maintaining their authority over specific territories,
thus sabotaging efforts for collaborative CPG develop-
ment work. As proposed elsewhere [23] and supported
by this study, a possible way forward would be for South
Africa to have a centrally coordinated CPG unit with
buy-in from and communication between public and
private stakeholders. It would be important for this unit
to help foster a political environment that promotes col-
laboration and integration between different CPG devel-
opment groups.
Simultaneously, the CPG arena was seen to be satu-
rated with personal, financial and political vested inter-
ests, and lacking processes for reporting and managing
these. The issue of conflicting interests is not unique to
South Africa. Globally, many guideline development
groups fail to adequately disclose and manage conflicts
of interests [36, 37]. Most certainly, guideline develop-
ment is never neutral, and is inevitably “a social as well
as technical process” that “necessarily reflect[s] value
judgments” [38]. However, clear procedures for the
documentation and management of interests, including
financial relationships and sources, are essential. The
varying perspectives participants in this study conveyed
around if and how conflicting interests can and should
be managed suggests that this is a complex issue in the
country. Further research on this topic in South Africa is
therefore needed, and substantial stakeholder input and
buy-in will be required if we are to move from how in-
terests have been managed to how they should be.
Finally, challenges pertaining to stakeholder engage-
ment were also described as related to power dynamics
in the country. The nature of CPG consultation was
perceived to favour those individuals and groups who
have the time, resources and capacity to provide input.
As such, and as reported in other studies in South Africa
[22, 39], the views of end-users of CPGs, ‘at the coal face’
of service delivery remain inadequately incorporated. As
suggested by participants in this present study, and simi-
larly highlighted elsewhere [40, 41], a failure to include
the perspectives of those who will be implementing
CPGs could have a dire impact on their effective uptake
and use. A noticeable absence in the stakeholders’ narra-
tives in this study pertains to the issue of patient in-
volvement. Internationally, patient engagement is now
recognised as an important component of CPG develop-
ment to ensure the production of more patient-centred
and trustworthy guidelines [42, 43]. The silence around
this topic in this study suggests that the involvement of
patients in CPG development clearly requires more at-
tention in South Africa.
Additionally, it emerged that the process of stakeholder
engagement tends to marginalise the opinions of individ-
uals and groups located in the more resource-limited
provinces in the country. This is indeed further supported
by the fact that, despite our attempts to include national
stakeholders from all provinces in the country in this
study, our final sample was dominated by participants
from Gauteng and Western Cape Provinces, two of the
country’s most well-resourced provinces. Read in conjunc-
tion with the study findings, this sample bias is likely to
reflect the reality of skewed power dynamics in CPG de-
velopment in South Africa, where many who lead national
knowledge production, and are therefore able to contrib-
ute their time to the process, may be based in the Western
Cape and Gauteng. Ultimately, all of this suggests that
CPG development in South Africa needs to develop more
innovative strategies for better reaching and including the
voices of those across professional hierarchies and
provinces in the country, as well patients and healthcare
consumers.
Study strengths and limitations
The strengths and limitations of the broader study in
which this sub-study is embedded, have been described
in detail elsewhere [23]. With regards to this sub-study
specifically, we have focused on the personal accounts
and experiences of respondents. A strength of this ap-
proach is that the data represents the perspectives of ac-
tors engaged directly with CPG activity in South Africa
and therefore provide valuable insights into the thinking
behind CPG development processes. However, we
recognise that such accounts are inevitably influenced
by respondents’ position at time of event, their position
at the time of being interviewed, their relationship with
the researchers and their memory of particular events
and processes [44]. Our final sample was dominated by
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participants from Gauteng and Western Cape Provinces,
and thus the views and perspectives of stakeholders who
may be involved in CPG development from other Prov-
inces in the country might not have been sufficiently
reflected. At the same time, we did not speak to patient
representative groups or patients, as it emerged during
our stakeholder ‘mapping exercise’ that these individuals
and groups are currently limited in their involvement
with CPG development in the country. Further research
in CPG development in South Africa, which tries to
reach more ‘marginalised’ stakeholders, including pa-
tients and patient representative groups, is needed.
Furthermore, and as noted in the previous paper [23],
the lead researcher, who was present at most interviews,
has experience in evidence synthesis for CPGs and
teaching about CPGs. As she may be known to some in-
terviewees as an advocate for evidence-based healthcare,
this may introduce response bias. Therefore, we ensured
that at least two interviewers were present, including
one who was not engaged in CPG activities, with the
intention to create more distance and, as much as pos-
sible, objectivity. In addition, and as described in the
methods section, the researchers discussed the findings
at regular intervals during the analysis process. This
helped to verify and refine the emerging themes and
provided an opportunity for our presuppositions (and
how they may be shaping the analysis) to be identified
and critically examined.
While the results of this study need to be generalised
with caution, as all qualitative research, we have suc-
ceeded in providing in-depth insight into CPG develop-
ment in South Africa. The results corroborate with and
extend the findings from other studies on this topic in
SSA and South Africa more specifically. The results also
shed light on key factors that might help to improve the
development of high-quality CPGs in South Africa, and
potentially other countries in the region.
Many of the findings in this study are similar to those
previously reported. However, two unique issues that
emerged, which have not received much discussion else-
where, were the complexities around managing conflicting
interests and adapting CPGs to within-country contextual
differences. Participants in this study held contrasting per-
spectives about these issues, suggesting the need for fur-
ther research into these factors and greater discussion
regarding how they should be addressed.
Conclusion
Growing awareness of the important role CPGs can play
in healthcare systems in SSA demands increased know-
ledge about CPG development activity in the region. Fo-
cusing on South Africa, this study has shown that, while
there is strong commitment amongst national stake-
holders to advance guideline development processes, a
complex mix of values, politics, power and capacity con-
straints pose significant challenges in this regard. More
dedicated resources for CPG development, together with
standardised conflict of interest policies and greater
guidance for trans-contextual CPG adaption will help
enhance the quality and credibility of CPGs for PHC
and have an associated positive impact on patient care
in the country. Cultivating a political environment that
fosters collaboration, reciprocity and more equitable in-
clusion within and between different CPG development
groups and stakeholders could help reduce duplication
of efforts, make better use of limited resources and
skills, and help redress historical inequities within the
South African healthcare context.
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